Pharma News
25 Jan 2026 to 31 Jan 2026
Jan 31, 2026
Longeveron granted Japanese patent for methods to evaluate human potency assays...
Longeveron Inc. has received a patent from the Japan Patent Office for potency assay methods related to human mesenchymal stem cells (MSCs), valid until April 2041. This patent enhances Longeveron's intellectual property portfolio, now totaling 33 patents. The company is advancing its lead product, laromestrocel (Lomecel-B), in clinical trials for conditions like Hypoplastic Left Heart Syndrome and Alzheimer’s disease.
Jan 31, 2026
International regulatory authorities emphasized the importance of antimicrobial labeling.
Global regulatory leaders emphasized the importance of antimicrobial labelling in combating antimicrobial resistance (AMR) during a meeting in Geneva on January 30, 2026. They highlighted that proper labelling is essential for the appropriate use and disposal of antimicrobial products, reinforcing its critical role in the global health strategy against AMR.
Jan 31, 2026
Eli Lilly plans to invest $3.5 billion in a new manufacturing facility in Pennsylvania as part of its expansion efforts in the United States.
Eli Lilly announced plans to build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth U.S. site, to produce injectable weight-loss medications, including retatrutide. The plant, expected to create 850 jobs, will begin construction in 2026 and be operational by 2031. This investment is the largest by a life sciences company in Pennsylvania's history.
Jan 31, 2026
Lack of Market Incentives for Innovation: The Underutilization of Drug Repurposing | ITIF
A recent NBER working paper highlights the challenges of drug repurposing, revealing that economic incentives often misalign with public health value. While repurposing existing drugs can unlock new therapies, firms are less likely to invest once market exclusivity expires. The authors suggest policy changes to enhance intellectual property protections and incentivize research, potentially leading to 200-800 additional drug uses.
Jan 30, 2026
How the pharmaceutical industry is managing a $300 billion patent expiration challenge | PharmaVoice
Big Pharma faces a potential $300 billion revenue loss by 2030 due to patent expirations, according to an Evaluate report. Companies like Eli Lilly and Novo Nordisk are well-positioned, while Bristol Myers Squibb, Merck, and Pfizer face significant challenges. Johnson & Johnson and AbbVie are employing innovative strategies to mitigate losses, with AbbVie successfully reducing reliance on Humira.
Jan 30, 2026
Individuals are experiencing the emergence of new eating disorders linked to GLP-1 medications.
A New York Post article highlights the darker side of GLP-1 drugs like Ozempic, which, while effective for weight loss and diabetes management, may lead to dangerous obsessions with food and body image. Experts warn of "agonorexia," where patients develop eating disorders or disordered eating behaviors. They call for better awareness and screening for mental health issues before prescribing these medications.
Jan 30, 2026
Novo Nordisk Increases Advertising Budget for Wegovy and Ozempic Following Improvement in Supply Issues, Outpacing Eli Lilly
Novo Nordisk A/S significantly increased its U.S. advertising for GLP-1 drugs Wegovy and Ozempic in 2025, spending approximately $487 million, compared to Eli Lilly's $214 million on Zepbound and Mounjaro. This marketing surge follows supply constraints in 2024. Despite the increased spend, Lilly's Zepbound has gained a larger market share, with 60% of the U.S. obesity drug market.
Jan 30, 2026
Essential Information for Pharmacists Regarding Most Favored Nation Amidst Increasing Drug Costs
Pharmaceutical companies, including Pfizer and Novo Nordisk, have agreed with the Trump Administration to reduce drug prices and adopt a most favored nation (MFN) pricing model. This initiative aims to lower costs for key medications like semaglutide (Ozempic, Wegovy) and apixaban (Eliquis). Pharmacists are advised to prepare for significant changes in workflows and patient counseling as these pricing adjustments take effect.
Jan 30, 2026
Allahabad High Court Supports the Decision to Summon Directors of Marion Biotech in Connection with Fake Cough Syrup Case
The Allahabad High Court has upheld the summoning of directors from Marion Biotech Pvt. Ltd. in connection with a spurious cough syrup case linked to child deaths in Uzbekistan. This ruling underscores the importance of public health safeguards and accountability within the pharmaceutical industry.
Jan 30, 2026
ANDA Litigation Resolutions - Q4 2025 | Robins Kaplan LLP - JDSupra
Numerous pharmaceutical patent cases have been dismissed without prejudice, including Pfizer's Xeljanz® and Gilead's Biktarvy®. Cipla is enjoined from infringing Gilead's patents, while Onyx's Kyprolis® claims against Somerset were also resolved. Other notable dismissals involve Novartis, Astellas, and AbbVie, with parties bearing their own costs. The FDA's approval processes remain unaffected.
Jan 30, 2026
Canada is set to become a key player in the worldwide competition for generic versions of Ozempic.
Italian lab equipment manufacturer Steriline has partnered with Applied Pharmaceutical Innovation to create a robotic filling line for generic semaglutide, the active ingredient in Ozempic, at API's Edmonton facility. With Novo Nordisk's patent protections expired, six companies are poised to enter the market, potentially transforming the weight-loss drug landscape in Canada, where demand is surging.
Jan 30, 2026
The upcoming billion-dollar blockbuster medication might be a psychedelic, but there's a significant issue to address.
Elizabeth, a participant in a clinical trial by Lykos (formerly MAPS PBC), believed she was treated with MDMA for PTSD but later learned she received a placebo. Despite this, she experienced significant healing, highlighting the power of expectation and therapeutic support. The trial's results raise questions about the efficacy of psychedelics versus placebo effects in mental health treatment.
Jan 30, 2026
My nightmare with unapproved 'fake Ozempic': Physicians prescribe inexpensive compounded medications to ... - Daily Mail
The FDA warns against using compounded semaglutide, a cheaper alternative to brand-name GLP-1 drugs like Ozempic and Wegovy, due to safety concerns. Compounded versions lack FDA approval and have been linked to severe health risks, including emergency room visits and deaths. Experts emphasize the importance of using regulated medications to avoid dangerous side effects and dosing errors.
Jan 30, 2026
Connecticut's Drug Price Limit Withstands Distributor Opposition, At Least for the Time Being - Law360 Healthcare Authority
The Second Circuit has upheld Connecticut's cap on generic and off-patent drug prices, rejecting a request from the Healthcare Distribution Alliance to block its enforcement. This decision allows the state to continue implementing the price cap for the time being.
Jan 30, 2026
India's Patent Legislation Under Scrutiny Regarding Access to SMA Medication - Whalesbook
The high cost of Spinal Muscular Atrophy (SMA) treatments in India remains a barrier, despite Natco Pharma's affordable version of Evrysdi, priced at ₹5 lakh annually. Patients are challenging the government's ₹50 lakh funding cap in court, citing violations of the right to life. The Supreme Court's decision could significantly impact access to essential medicines in India.
Jan 30, 2026
Limited Information Yet "Impenetrable" Safeguards: The Upholding of a Salt Form Patent in China
Incyte Corporation's Chinese patent for Ruxolitinib salt forms has survived an invalidation challenge, as the CNIPA upheld its validity, citing sufficient disclosure and priority entitlement. The decision highlights the importance of common knowledge in JAK research and the predictability of salt formation in pharmaceuticals, reinforcing the patent's robustness in China amid ongoing challenges.
Jan 29, 2026
This artificial intelligence possesses knowledge in chemistry and assists in the creation of 35 novel drugs and materials - Nature
Researchers have developed an AI system named MOSAIC, which streamlines chemical synthesis by generating laboratory instructions for creating new compounds. Described in a study published in Nature, MOSAIC can potentially enhance drug discovery and product development in pharmaceuticals, agrochemicals, and cosmetics. The system utilizes a specialized approach, improving accuracy and efficiency in chemical reactions.
Jan 29, 2026
Glucotrack secures additional patents for its continuous blood glucose monitoring device.
Glucotrack (Nasdaq:GCTK) has received three new U.S. patents for its continuous blood glucose monitoring (CBGM) platform, enhancing its intellectual property and competitive edge. The patents cover key technologies for a device designed for three years of accurate blood glucose monitoring without external components. Glucotrack plans to submit the system for FDA investigational device exemption in spring.
Jan 29, 2026
Husch Blackwell Achieves Federal Circuit Win for TWi Pharmaceuticals in Hatch-Waxman Case...
A Husch Blackwell trial team successfully defended TWi Pharmaceuticals against Merck KGaA's patents for the multiple sclerosis drug Mavenclad® (cladribine). The Federal Circuit declined to reconsider a decision affirming the invalidation of Merck's patents, which TWi argued were obvious based on prior work. Mavenclad® generated €1.1 billion in sales in 2024.
Jan 29, 2026
CNIPA supports generic pharmaceutical company in conflict regarding mirogabalin besylate tablets.
On December 3, 2025, the CNIPA ruled that Chengdu Easton Biopharmaceuticals' generic mirogabalin besylate tablets do not infringe Daiichi Sankyo's formulation patent. Mirogabalin, marketed as Tarlige, is approved for diabetic peripheral neuropathic pain. The ruling is appealable within six months, highlighting the complexities of patent claims and the importance of formulation patent strategies.
Jan 29, 2026
Supreme Court to consider inducement allegations involving generic drugs | JD Supra
The Supreme Court will review Amarin Pharma's case against Hikma Pharmaceutical USA regarding induced infringement claims. The Federal Circuit ruled that Hikma's marketing of its generic version of Vascepa, despite carving out a patented use, could still lead to liability. Hikma argues this undermines the Hatch-Waxman Act's protections for generic manufacturers.
Jan 29, 2026
Chong Kun Dang secures South Korea's first approval for a generic version of Tagrisso, but AstraZeneca's appeal delays the launch until 2033.
Chong Kun Dang has received Korea's first marketing approval for a generic version of AstraZeneca's lung cancer drug Tagrisso (osimertinib), branded as Otinib, in 40 mg and 80 mg strengths. The approval could lead to a nine-month exclusivity period if ongoing patent litigation is resolved favorably. The company aims for a 2033 launch, pending patent outcomes.
Jan 29, 2026
Canada's government reveals the new Chairperson for the Patented Medicine Prices Review Board.
The Honourable Marjorie Michel, Minister of Health, announced Anie Perrault as the new Chairperson of the Patented Medicine Prices Review Board (PMPRB) until August 2028. Perrault, previously Vice-Chairperson, will lead the Board in monitoring and reviewing drug prices, following the implementation of new Guidelines on January 26, 2026, aimed at protecting Canadian consumers.
Jan 29, 2026
Exploring the Reasons Behind the Varying Effectiveness of Ozempic and GLP-1 for Different Individuals
Recent research highlights the limitations of GLP-1 drugs like Ozempic, Wegovy, and Zepbound in treating obesity, revealing that obesity is a complex condition with various biological factors. Personalized treatment approaches, including genetic testing, are emerging to tailor therapies to individual needs. Experts emphasize that while GLP-1 drugs are effective for some, lifestyle changes remain crucial for long-term success.
Jan 29, 2026
Intensified Efforts Against Counterfeit and Unauthorized Medications in Bihar and UP: Numerous Raids Reveal...
Authorities in Bihar and Uttar Pradesh have conducted multiple raids targeting illegal drug trade, uncovering unlicensed medical stores and the distribution of potentially fake or substandard medicines. The crackdown involved entities such as Bharat Medical Agency and Mahavir Hospital and Trauma Center, emphasizing the ongoing battle against counterfeit pharmaceuticals in the region.
Jan 29, 2026
Sanofi aims for a sales increase in the high single digits by 2026 and intends to initiate a share repurchase program.
Sanofi, a leading vaccine manufacturer, anticipates "slightly negative" vaccine sales in 2026 due to U.S. policy changes and anti-vaccine sentiments. CEO Paul Hudson emphasized the need to defend vaccine efficacy. The company faces challenges as its blockbuster asthma drug Dupixent nears patent expiration, with CFO François-Xavier Roger noting it will be hard to replace. Sanofi plans strategic acquisitions and a €1 billion share buyback.
Jan 29, 2026
The Otsuka Ruling - Formulations have been released, but will there be extensions on patent terms for specific active pharmaceutical ingredients?
The Australian Federal Court's Otsuka decision has deemed patents for pharmaceutical formulations ineligible for pharmaceutical term extensions (PTEs), impacting Otsuka Pharmaceutical's aripiprazole formulation. This ruling may also affect patents for certain first-generation active pharmaceutical ingredients (APIs), including nucleic acid sequences. IP Australia has paused PTE applications pending further review, with a potential appeal to the High Court in February 2026.
Jan 29, 2026
Eli Lilly's $1 Billion Investment in Genetic Therapies - AD HOC NEWS
Eli Lilly is diversifying its portfolio by entering gene therapy through a collaboration with Seamless Therapeutics, targeting therapies for hearing loss. This strategic move comes as the company prepares for its fourth-quarter earnings report on February 4, 2026, with revenue expectations of $17.9 billion. Despite recent stock declines, analysts view this as a consolidation phase amid competitive pressures.
Jan 29, 2026
Sanofi Reports Strong Q4 Earnings and Anticipates Profitable Expansion by 2026 - Finviz
Sanofi (SNY) reported Q4 2025 adjusted earnings of 89 cents per share, surpassing estimates, while net sales rose 7% to $13.2 billion but missed expectations. Key growth drivers included Dupixent, with sales of €4.25 billion, and Altuviiio, generating €324 million. Sanofi anticipates continued growth in 2026, planning a €1 billion stock buyback.
Jan 29, 2026
Eli Lilly Allocates Billions to Expand Beyond Major Pharmaceutical Products
Eli Lilly is investing profits from its weight-loss drugs into expansion, announcing two partnerships worth nearly $3 billion. Collaborations include a $1.12 billion deal with Seamless Therapeutics for gene therapies for hearing loss and a $1.93 billion alliance with Repertoire Immune Medicines for autoimmune treatments. Despite recent stock pressure, analysts remain optimistic about long-term growth.
Jan 28, 2026
Can Ozempic medications for pets assist in weight loss? - The Palm Beach Post
A University of Florida study led by Dr. Chen Gilor is exploring the effects of GLP-1 weight-loss drugs, similar to Ozempic, on obese cats. The study involves 50 cats receiving six-month under-the-skin capsules. With over 60% of U.S. cats considered obese, the research could pave the way for effective weight management solutions for pets, mirroring human treatments.
Jan 28, 2026
Pharmaceutical sector sees FDI equity inflow rise to $1.27 billion in the first half of FY26, according to DrugsControl Media Services.
Foreign Direct Investment (FDI) equity inflow into India's drugs and pharmaceuticals sector surged to $1.27 billion in the first half of FY26, marking over a two-fold increase compared to the same period last year. This significant growth highlights the sector's expanding appeal to international investors.
Jan 28, 2026
Important details: Novartis is dealing with the expiration of patents; Citigroup has assigned a 'buy' rating - TradingView
Novartis is confronting revenue challenges from upcoming patent expirations on key drugs and is considering biotech acquisitions to bolster its intellectual property pipeline. Citigroup has issued a 'buy' rating for Novartis, highlighting its status as a 'consistent earnings outperformer' and the potential of several multi-billion-dollar drugs in its pipeline.
Jan 28, 2026
Emerging Trends in Biopharma Mergers and Acquisitions: Four Key Factors Influencing Deals This Year - Fierce Biotech
Biopharma M&A activity is shifting focus from blockbuster drugs to enhancing capabilities across the drug development process, according to Bain & Company's Global M&A Report 2026. Pharma deal value surged 79% through November 2024, driven by trends like vertical integration and the rise of antibody-drug conjugates (ADCs). Roche's $570 million deal for MedLink Therapeutics highlights this trend.
Jan 28, 2026
Transforming Rare Disease Treatments: From Specialized Trials to a Key Growth Driver
The article discusses the evolution of rare disease drug development, highlighting the impact of the US Orphan Drug Act of 1983, which incentivized investment in therapies for small patient populations. Today, one-third of FDA-approved drugs have orphan designations, with successful therapies like Spinraza and Zolgensma proving the commercial viability of rare disease treatments. Future challenges include rising launch prices and payer scrutiny.
Jan 28, 2026
Expectations for Merck's Q4 Performance in Non-Oncology Medications - TradingView
Merck (MRK) is set to report its Q4 and full-year 2025 results on February 3, with a focus on Keytruda sales, which accounted for over 50% of its pharmaceutical revenue. New products like Capvaxive and Winrevair are expected to drive growth amid Keytruda's impending patent loss. Merck's stock has risen 30.6% in six months, outperforming the industry.
Jan 28, 2026
Merck's Q4 Results for Non-Oncology Medications: Anticipations Ahead - The Globe and Mail
Merck (MRK) is set to report its Q4 and full-year 2025 results on February 3, with a focus on Keytruda sales, which accounted for over 50% of its pharmaceutical revenue. New drugs Capvaxive and Winrevair are expected to drive growth amid Keytruda's impending patent loss. Merck's stock has risen 30.6% in six months, outperforming the industry.
Jan 28, 2026
The $300 Billion Challenge Facing Big Pharma and Its $1.2 Trillion Answer | Chaikin Analytics
The pharmaceutical industry faces a significant patent cliff, with over $300 billion in drug revenues set to lose protection by 2030. This has sparked a surge in mergers and acquisitions, as companies seek to replenish their pipelines. With $1.2 trillion in cash available, the competition for innovative biotech assets is intensifying, presenting both opportunities and risks for investors.
Jan 28, 2026
Lilly Enters into Smooth Gene-Editing Agreement Worth More Than $1.1 Billion - Bloomberg
Eli Lilly & Co. has entered a partnership valued at over $1.1 billion with Seamless Therapeutics GmbH to develop gene therapies for hearing loss. Seamless will create programmable recombinases to correct gene mutations, while Lilly will obtain exclusive rights to use these enzymes for developing experimental drugs.
Jan 28, 2026
Bristol-Myers Squibb Stock Forecast: Are Analysts Optimistic or Pessimistic? - Palmetto Grain Brokerage -
Bristol-Myers Squibb Company (BMY) has faced an 8.3% decline over the past year, underperforming the S&P 500, primarily due to concerns over patent expirations for key drugs like Eliquis and Opdivo. However, analysts project a 455.7% EPS growth for FY2025 and have upgraded BMY to a “Moderate Buy,” citing a strong R&D pipeline and recent FDA approval of Breyanzi.
Jan 28, 2026
Lawsuits claim significant side effects from GLP-1 weight-loss medications - USA Today
Three individuals have filed lawsuits against drug manufacturers Novo Nordisk and Eli Lilly, alleging severe injuries linked to GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro. Claims include blindness, colon rupture, and neurological issues. The lawsuits argue that the companies failed to adequately warn users of these risks, as usage of these drugs has surged among Americans.
Jan 28, 2026
Merck KGaA vs. Hopewell Pharma Ventures, Inc. | Robins Kaplan LLP - JDSupra
Merck KGaA has successfully maintained a regulatory stay on the approval of generic cladribine (Mavenclad®) after Hopewell Pharma Ventures sought to lift the stay, claiming competitive harm. The court ruled that it lacked the authority to alter the stay, emphasizing that Hopewell's actions in filing an IPR contributed to the delay. The Federal Circuit affirmed the decision to invalidate Hopewell's claims.
Jan 28, 2026
Supreme Court's Ruling on 'Skinny Label' Generic Drug Approval Could Be Influenced by Limited Information
The Supreme Court will review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. regarding the marketing of generic drugs with "skinny" labels, which omit certain patented uses. The case centers on Hikma's generic version of Vascepa (icosapent ethyl) and whether its promotional statements induce patent infringement. The decision could clarify limits on generic marketing practices.
Jan 28, 2026
Steering Through Challenges: Novo Nordisk Encounters a Crucial Year in 2026 - AD HOC NEWS
Novo Nordisk faces significant challenges as it prepares for its Q4 2025 financial results on February 4. With patent expirations and rising competition from Eli Lilly in the GLP-1 segment, CEO Mike Doustdar anticipates a tougher market. The company is launching oral Wegovy, priced at $149, to attract new demographics and counteract the impact of compounded drugs.
Jan 28, 2026
Is it possible to patent drugs developed by AI? (Podcast)
AI is revolutionizing drug discovery, but companies face challenges in patenting AI-assisted inventions due to unclear inventorship rules. Experts emphasize the need for documentation of human-AI interactions to establish inventorship. Without patent protection, the incentive for innovation may diminish, impacting future drug development. Legal clarifications are expected in the coming years.
Jan 28, 2026
A study reveals that an increasing number of high-income nations are utilizing compulsory licenses to obtain medications.
A recent study published in BMJ Global Health reveals that high-income countries significantly increased their use of compulsory licenses for accessing medicines, rising from 15% to 54% over a decade. This trend primarily targets treatments for noncommunicable diseases like cancer and cystic fibrosis, as well as Covid-19, amidst ongoing controversies surrounding such licenses.
Jan 28, 2026
Inventage Lab Obtains National Patent for Extended-Release Injectable Technology for Oral Weight Loss Medication
Inventage Lab Co., Ltd. has secured a domestic patent for its technology to formulate the GLP-1 class small molecule "Orforglipron" as a long-acting injectable for obesity and diabetes treatment. This innovation aims to enhance patient adherence by providing effects lasting one to three months, while minimizing gastrointestinal side effects. The drug is under development by Eli Lilly.
Jan 27, 2026
India expected to maintain its position on EU data exclusivity and intellectual property requests; potential reduction of pharmaceutical duties.
India and the EU are set to finalize a free trade agreement (FTA) on January 27, which will phase out import duties on pharmaceuticals, easing EU drug entry into India. However, India resists EU demands for stricter intellectual property rights and data exclusivity, fearing it could harm its generics industry. Major Indian exporters are targeting the EU's $2 billion biosimilars market.
Jan 27, 2026
Significant India-EU Trade Agreement May Affect Costs of Weight Loss and Essential Medications, Here's What to Know
India and the EU have finalized a historic Free Trade Agreement (FTA) after nearly two decades, aiming to reduce tariffs on goods, including pharmaceuticals. This deal could lower costs for imported medicines, particularly weight-loss drugs like semaglutide and tirzepatide. While initial price reductions are expected, significant changes may take years as local manufacturing and competition increase.
Jan 27, 2026
Scholars from the Solomon Center Highlight the Importance of Supreme Court Case on Drug Patent Liability
The U.S. Supreme Court will hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., focusing on "skinny labeling" for generic drugs. The case could impact generic competition and access to affordable medications, as research indicates that liability risks may deter generic manufacturers. A decision is anticipated later this year, with implications for the Hatch-Waxman Act's balance between patent protection and generic drug availability.
Jan 27, 2026
Mylan achieves a partial victory against Sanofi's attempt to dismiss antitrust allegations in the US - MLex
Mylan has achieved a partial victory in its antitrust case against Sanofi-Aventis regarding alleged monopolization and delays in the injectable insulin glargine market. While Mylan's claims related to a "product hop" theory were dismissed, it has been granted the opportunity to amend its allegations.
Jan 27, 2026
United Therapeutics Corporation vs. Liquidia Technologies, Inc. | Robins Kaplan LLP - JDSupra
United Therapeutics Corp. has filed a lawsuit against Liquidia Technologies, alleging infringement of its U.S. Patent No. 11,357,782 related to Tyvaso® (treprostinil). The court denied Liquidia's motion to dismiss, ruling that the claims are distinct from previous cases involving Liquidia's Yutrepia product. The case centers on the differences between the '782 and '793 patents, with the court finding no claim preclusion or issue preclusion applicable.
Jan 27, 2026
Novo Nordisk or Viking: Which Obesity Treatment Stock is the More Secure Investment? - TradingView
Novo Nordisk (NVO) and Viking Therapeutics (VKTX) are key players in the obesity treatment market. NVO's semaglutide drugs, including Ozempic and Wegovy, dominate the GLP-1 space, while VKTX's investigational VK2735 shows promise but faces safety concerns. Despite recent challenges, NVO is viewed as a safer investment due to its established revenue base, while VKTX remains high-risk with no approved products.
Jan 27, 2026
Akari Therapeutics Submits Important Patent and Launches Second ADC Initiative AKTX-102 Aimed at ...
Akari Therapeutics has expanded its ADC pipeline with the new candidate AKTX-102, targeting the challenging oncology marker CEACAM5. The company filed a U.S. provisional patent for this first-in-class ADC, which utilizes its proprietary PH1 spliceosome payload. Akari aims to enhance cancer treatment efficacy while advancing its lead program, AKTX-101, towards clinical trials.
Jan 27, 2026
Drug Manufacturers Invest Heavily in Lobbying for Weight-Loss Medications
Pharmaceutical companies, including Novo Nordisk and Eli Lilly, spent millions lobbying the federal government on GLP-1 weight-loss drugs amid rising scrutiny over pricing. Despite public agreements with the Trump administration to lower costs, they continued lobbying on pricing and Medicare coverage. Other companies like Boehringer Ingelheim and Johnson & Johnson also engaged in lobbying efforts related to obesity treatments.
Jan 27, 2026
Roche's Obesity Medication Shows Promising Phase 2 Results, Yet the Real Challenge Might Arise From ...
Roche's obesity drug CT-388 has shown a placebo-adjusted weight loss of 22.5% in a Phase 2 trial, comparable to other treatments. The drug targets GLP-1 and GIP receptors, similar to Eli Lilly's Zepbound. Roche plans to advance CT-388 to Phase 3 testing and explore its combination with Zealand Pharma's petrelintide to enhance efficacy in a competitive market.
Jan 27, 2026
In December, 16 states and 6 Union Territories failed to provide NSQ data to the CDSCO, according to DrugsControl Media Services.
In December, India's drug regulators reported 167 drug samples as Not of Standard Quality (NSQ). However, 16 states and six Union Territories failed to submit their NSQ data to the Central Drugs Standard Control Organization (CDSCO), raising concerns about compliance and oversight in drug quality monitoring.
Jan 26, 2026
Novo Nordisk's Oral Weight-Loss Medication Generates Positive Sentiment Among Investors - AD HOC NEWS
Shares of Novo Nordisk have surged nearly 19% following the U.S. launch of its oral weight-loss drug, Wegovy. Despite early demand with 18,000 prescriptions in the first week, CEO Mike Doustdar cautioned about international challenges and competition from Eli Lilly. The global GLP-1 market is projected to reach $100 billion by 2030, intensifying rivalry in obesity treatments.
Jan 26, 2026
Eli Lilly vs. Viking Therapeutics: Which Stock Has Greater Potential to Create Millionaires?
Eli Lilly and Viking Therapeutics are both key players in the rapidly growing obesity drug market, projected to reach nearly $100 billion by 2030. Eli Lilly's Mounjaro and Zepbound have generated over $10 billion in sales, while Viking's candidates are in late-stage trials. Both companies show potential for significant growth, but Viking carries more risk due to its developmental stage.
Jan 26, 2026
How Will Sales of Ozempic and Wegovy Impact NVO's Q4 Performance? - Finviz
Novo Nordisk (NVO) continues to dominate the cardiometabolic market with its semaglutide-based drugs, Ozempic and Wegovy, generating DKK 152.5 billion in sales in 2025. Despite facing competition from Eli Lilly's Mounjaro and Zepbound, NVO's recent FDA approval of an oral Wegovy pill is expected to enhance sales. However, sales growth for Ozempic and Wegovy may slow due to market pressures.
Jan 26, 2026
A pharmaceutical firm based in Alderley Park achieves a significant milestone with a Canadian patent for its addiction treatment medication.
Alderley Park-based TheraCryf has secured a Canadian patent for its addiction treatment drug, Ox-1, completing coverage in major markets. COO Dr. Helen Kuhlman highlighted the patent's significance for the program's long-term value. The company reported a post-tax loss of £1.3m for the half-year ending September 30, 2025, but has a cash runway until late 2026.
Jan 26, 2026
Raipur Drug Operation Uncovered: Rs 50 Lakh in Unbilled Medications Confiscated
Authorities in Raipur have uncovered a drug racket involving the distribution of unlicensed medicines, seizing drugs worth Rs 50 lakh. The operation revealed fake invoices and collusion with inspectors, highlighting a significant issue in the spurious drugs network in Chhattisgarh.
Jan 26, 2026
Kim Youngjoo, the CEO of Chong Kun Dang, stated: "The reform of drug pricing contradicts market principles and increases...
A policy debate on January 26 addressed the government's proposed drug pricing reform, which aims to lower generic drug prices from 53.55% to 40% of original drug prices. Industry leaders, including Kim Youngjoo of Chong Kun Dang and Yoon Jaechoon of Daewoong Pharmaceutical, criticized the plan for potentially maintaining high prices for original drugs and questioned its effectiveness in achieving fiscal savings.
Jan 26, 2026
Misuse of Medications: Codeine Cough Syrup, Tramadol, Pregabalin, and Other Frequently Abused Substances...
In late January 2026, police in northern and central India conducted anti-narcotics operations, seizing Codeine Cough Syrup, Tramadol, and Pregabalin among other abused substances. The operations led to multiple arrests across Rajasthan, Uttar Pradesh, Punjab, Bihar, and Chhattisgarh, targeting drug diversion networks.
Jan 26, 2026
Fraudulent Billing Scheme Uncovered, Three Additional Pharmaceutical Companies Under Investigation as Inquiry Expands
Ghaziabad police, alongside the Drug Department, have dismantled a significant cancer drug trafficking ring involving fake billing and the unauthorized sale of expired medications. The investigation has expanded to include three new pharmaceutical companies as authorities continue to probe the illegal operations.
Jan 26, 2026
Patent Expiration of Ozempic Triggers Lobbying Conflict in Brazil - January 26, 2026 - Folha - UOL
The impending expiration of Novo Nordisk's Ozempic patent in Brazil has sparked a congressional dispute. The company seeks a five-year extension due to alleged delays in patent approval, while local firms advocate for generics. Brazilian courts have previously blocked extension attempts, raising concerns over public health and access to affordable medications.
Jan 26, 2026
Supreme Court to Hear Hikma v. Amarin: A Crucial Examination of Skinny Labeling | JD Supra
The U.S. Supreme Court will hear Hikma v. Amarin, a case concerning induced patent infringement related to Hikma's generic version of Vascepa (icosapent ethyl). The Court will decide if a generic with "skinny labeling" can induce infringement of patents for carved-out uses. The outcome could significantly impact how generic drugs are marketed.
Jan 26, 2026
The Drug Price Negotiation Program implemented by the Federal Government may potentially breach its own regulations...
The U.S. Court of Appeals upheld the Inflation Reduction Act (IRA), allowing drug price negotiations for Medicare, but Bristol Myers Squibb and Janssen Pharmaceuticals have appealed to the Supreme Court, arguing it violates constitutional rights. The IRA could impact access for 160 million patients and stifle pharmaceutical innovation by imposing price controls, raising concerns about long-term effects on drug development.
Jan 26, 2026
Anticipations are rising regarding Alteogen's profit framework for the medium to long term, which has delivered
Merck's Keytruda SC conversion rate is initially projected at 30-40%, but some analysts, including UBS, anticipate it could reach 70%. This could lead to significant annual sales, with Alteogen set to benefit from a 2% royalty. The contract allows for stable cash flow until 2043, potentially yielding 1.4 trillion won in royalties by 2028.
Jan 25, 2026
Eli Lilly's Stock Experiences Strain Due to Changes in Key Medication Approval Schedule - AD HOC NEWS
Eli Lilly faces a regulatory delay for its oral GLP-1 medication, orforglipron, with the FDA pushing the decision date to April 10. This news caused a 2.1% drop in Eli Lilly's stock, which has fallen over 12% since January. Despite this setback, the company remains strong in the obesity and diabetes markets with its injectable treatments Zepbound and Mounjaro.
Jan 25, 2026
EMILY STACK: Families Suffering Due to Pharmaceutical Companies' Legal Tactics | The Daily Caller
Moms for America highlights the rising costs of healthcare, with nearly one in five Americans rationing medications. President Trump is promoting TrumpRX to help families buy medicines directly from manufacturers and is urging Congress to support access to affordable generic drugs. The article calls for reform to combat abusive patent practices that delay generic drug entry, ultimately aiming to lower healthcare costs for families.
Jan 25, 2026
Two Lesser-Known Biotech Companies Poised for Growth in 2026 - The Globe and Mail
Halozyme Therapeutics and Catalyst Pharmaceuticals report strong revenue and EPS growth, with Halozyme's shares up over 25% and Catalyst's by 3% in the past year. Halozyme's Enhanze platform boosts its drug-delivery systems, while Catalyst focuses on rare diseases. Both companies maintain low debt and attractive valuations, positioning them well for continued growth in 2026.
Jan 25, 2026
Chugai and Roche's new obesity medication seeks to prevent weight regain - Nikkei Asia
Chugai Pharmaceutical, a Roche subsidiary, plans to seek approval for a new obesity drug by 2028. The drug aims to prevent the return of excess body weight after treatment, according to Nikkei.
